These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1377429)

  • 21. Histopathologic characterization of hereditary benign prostatic hyperplasia.
    Doehring CB; Sanda MG; Partin AW; Sauvageot J; Juo H; Beaty TH; Epstein JI; Hill G; Walsh PC
    Urology; 1996 Oct; 48(4):650-3. PubMed ID: 8886078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT; Calhoun E; Jacobsen SJ
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
    Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
    J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative and total volume of histological components in benign prostatic hyperplasia: relationships between histological components and clinical findings.
    Ishigooka M; Hayami S; Hashimoto T; Suzuki Y; Katoh T; Nakada T
    Prostate; 1996 Aug; 29(2):77-82. PubMed ID: 8700803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
    Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
    Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia.
    Crispo A; Talamini R; Gallus S; Negri E; Gallo A; Bosetti C; La Vecchia C; Dal Maso L; Montella M
    Urology; 2004 Oct; 64(4):717-22. PubMed ID: 15491708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transurethral laser therapy and urinary tract infections.
    Miller J; Ludwig M; Schroeder-Printzen I; Schiefer HG; Weidner W
    Ann Urol (Paris); 1996; 30(3):131-8. PubMed ID: 8766150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dietary patterns and surgically treated benign prostatic hyperplasia: a case control study in Western Australia.
    Ambrosini GL; de Klerk NH; Mackerras D; Leavy J; Fritschi L
    BJU Int; 2008 Apr; 101(7):853-60. PubMed ID: 18070188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation of benign prostatic hyperplasia with hyperlipemia].
    Li PJ; Zhang XH; Guo LJ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benign prostatic hyperplasia: age-related tissue-remodeling.
    Untergasser G; Madersbacher S; Berger P
    Exp Gerontol; 2005 Mar; 40(3):121-8. PubMed ID: 15763388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.
    Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
    J Urol; 1999 Oct; 162(4):1301-6. PubMed ID: 10492184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inflammatory changes in the obstructed prostate: the correlation between the bacteriological and histological findings].
    Soler Soler JL; Martínez Torres JL; Hidalgo Domínguez Mdel R; Lardelli Claret P; Liébana Ureña J; Zuluaga Gómez A; Saharour G
    Arch Esp Urol; 1999 Sep; 52(7):729-38. PubMed ID: 10540763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
    Berger AP; Horninger W; Bektic J; Pelzer A; Spranger R; Bartsch G; Frauscher F
    BJU Int; 2006 Sep; 98(3):587-90. PubMed ID: 16796699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study.
    Zlotta AR; Raviv G; Peny MO; Noel JC; Haot J; Schulman CC
    J Urol; 1997 Mar; 157(3):894-9. PubMed ID: 9072594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The chimpanzee as a model of human benign prostatic hyperplasia.
    Steiner MS; Couch RC; Raghow S; Stauffer D
    J Urol; 1999 Oct; 162(4):1454-61. PubMed ID: 10492237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relation between benign prostatic hyperplasia and obesity and estrogen].
    Matsuda T; Abe H; Suda K
    Rinsho Byori; 2004 Apr; 52(4):291-4. PubMed ID: 15164594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of primary hypertension on hematuria of the patients with benign prostatic hyperplasia.
    Guo LJ; Tang Y; Guo CM; Zhang XH
    Chin Med J (Engl); 2010 May; 123(9):1154-7. PubMed ID: 20529555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.